Sponsors / ALKS
ALKS

Alkermes, Inc.

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
10Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757Alkermes, Inc.Phase 3Completed2023-09-06Actual
Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229Alkermes, Inc.Phase 3Enrolling by invitation2027-09Estimated
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Alkermes, Inc.Phase 3Recruiting2026-09Estimated
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950Alkermes, Inc.Phase 2Completed2025-06-19Actual
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2NCT06555783Alkermes, Inc.Phase 2Completed2025-11-11Actual
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683Alkermes, Inc.Phase 2, Phase 3Recruiting2028-06Estimated
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590Alkermes, Inc.Phase 2Active not recruiting2026-11Estimated
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1NCT07455383Alkermes, Inc.Phase 3Recruiting2027-05Estimated
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443Alkermes, Inc.Phase 3Recruiting2027-05Estimated
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)NCT07540897Alkermes, Inc.Phase 3Recruiting2027-06Estimated

Latest recorded trial changes